Objective: This prospective cohort study aimed to compare the clinical efficacy and safety of goserelin 10.8 mg administered trimonthly with goserelin 3.6 mg administered monthly in premenopausal females with symptomatic adenomyosis.
Methods: We recruited 139 premenopausal females with adenomyosis who complained of dysmenorrhea and/or menorrhagia. The first group ( = 70) received a single subcutaneous injection of goserelin 10.8 mg, and the second group ( = 69) received monthly subcutaneous goserelin 3.6 mg administered for 3 months. Follow-up was performed at the outpatient department after 12 weeks.
Results: Ultimately, 130 patients completed the study, including 68 and 62 patients in the goserelin 10.8 mg ( = 70) and 3.6 mg ( = 69) groups, respectively. We observed a significant decrease in the dysmenorrhea (NRS) score, uterine volume, and cancer antigen 125 (CA125) levels, and a significant increase in hemoglobin (HGB) levels in both treatment groups. There was no significant difference between the two groups. The sum of the adverse event scores was slightly higher in the goserelin 3.6 mg than in the 10.8 mg group.
Conclusions: The clinical efficacy of trimonthly administration of goserelin 10.8 mg was equivalent to monthly 3.6 mg dosing and was non-inferior regarding safety and tolerability. Hence, it can be a more cost-effective and convenient alternative treatment option in premenopausal females with symptomatic adenomyosis.
Trial Registration: ChiCTR2200059548.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09513590.2022.2160435 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Luteinizing hormone-releasing hormone receptor agonists and antagonists in prostate cancer: effects on long-term survival and combined therapy with next-generation hormonal agents.
Cancer Biol Med
December 2024
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
Prostate cancer is a leading cause of cancer-related death in men worldwide. Luteinizing hormone-releasing hormone receptor (LHRH-R) agonists and antagonists are known to achieve castration-level testosterone suppression; however, long-term data comparing the survival benefits of these therapies are insufficient to inform treatment decisions. Furthermore, the advent of next-generation hormonal agents (NHAs), such as abiraterone and enzalutamide, have shifted the paradigm of managing prostate cancer.
View Article and Find Full Text PDFReversal of Endometriosis-Induced Unilateral Ureteral Obstruction and Hydronephrosis With Medical Therapy.
Cureus
November 2024
Obstetrics and Gynecology, Hung Vuong Hospital, Ho Chi Minh, VNM.
Endometriosis is a common condition among women of reproductive age worldwide, with the urinary tract being the second most frequently affected extragenital organ system, particularly the bladder and ureters. Ureteral endometriosis (UE) is relatively rare, often asymptomatic, and can lead to progressive renal function loss if not addressed promptly. Early diagnosis and intervention are essential, requiring a high index of suspicion.
View Article and Find Full Text PDFMulticenter, prospective, single-arm clinical study to investigate the efficacy and safety of Zoladex (Goserelin acetate) 10.8 mg prior to surgery in Chinese premenopausal women with symptomatic uterine fibroids.
Gynecol Endocrinol
December 2024
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Article Synopsis
- The study aimed to evaluate the effectiveness and safety of Goserelin acetate (Zoladex) 10.8 mg in patients with uterine fibroids, with assessments made before and after a 12-week treatment period, leading up to surgery.
- After treatment, significant reductions were observed in uterine and fibroid volumes, along with decreased levels of hormones like estrogen, while hemoglobin levels increased, indicating improved anemia symptoms.
- The results indicated that Goserelin acetate is both effective in managing uterine fibroids and safe, with a high incidence of adverse events but overall good tolerance reported among patients.
Ribociclib-induced autoimmune-like hepatitis: a case report.
J Chemother
November 2024
Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkiye.
Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer represents the most prevalent subtype of breast cancer. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, in combination with endocrine therapy (ET), have shown substantial benefits in improving progression-free survival and, for ribociclib, an overall survival advantage. Despite clinical benefits, ribociclib is associated with elevated liver enzymes and severe liver dysfunction.
View Article and Find Full Text PDFDisseminated superficial actinic porokeratosis in an elderly patient undergoing androgen deprivation therapy for advanced prostate cancer: exploring the potential association.
Dermatol Reports
September 2024
Department of Dermatology and Venereology, Faculty of Medicine Universitas Indonesia; Dr. Cipto Mangunkusumo National Central General Hospital, Central Jakarta, Indonesia.
Porokeratosis is a group of chronic dermatoses characterized by the presence of cornoid lamellae. Disseminated superficial actinic porokeratosis (DSAP) is a common subtype, presenting as multiple small annular scaly lesions primarily in sun-exposed areas. While previous studies have documented DSAP in prostate cancer patients, the association with androgen deprivation therapy (ADT) has not been reported.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!